1. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab- Treated Patients With Relapsed or Refractory Multiple Myeloma 
Ajai Chari, Suzanne Arinsburg, Sundar Jagannath, Toshihisa Satta, Ivey Treadwell, Donna Catamero, Gillian Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan, Parul Doshi, Saad Usmani 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 1, Pages (January 2018)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 44-51DOI: (10. 1016/j
Clinical Lymphoma, Myeloma and Leukemia  , 44-51DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 1
Mechanism of Daratumumab Interference in IATs. In IAT, antibodies to minor antigens on reagent RBCs are detected by agglutination (A and B). Daratumumab present in serum of patients’ receiving treatment binds to donor or reagent RBCs in IAT, causing panagglutination, which masks presence of antibodies to minor antigens (C). To simplify representation of this mechanism, CD38 molecules present on RBCs are not shown in (A) and (B), and minor antigens are not shown in (C)
Abbreviations: IAT = indirect antiglobulin test; RBC = red blood cell.
Clinical Lymphoma, Myeloma and Leukemia  , 44-51DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions